Alnylam, Tenaya Announce $1.1B Cardiovascular Drug Pact

Tenaya Therapeutics stock jumps on research collaboration with Alnylam Pharmaceuticals.

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

Tenaya Therapeutics (TNYA) stock rose around 10% in premarket trading on Thursday after the company announced a research collaboration with Alnylam Pharmaceuticals (ALNY) to discover new cardiovascular drugs. The deal is worth up to $1.1 billion in potential milestone payments.

Why it matters

The partnership between the two biotech firms combines Tenaya's expertise in cardiovascular disease research with Alnylam's leadership in RNA interference (RNAi) therapeutics, potentially leading to innovative new treatments for heart conditions.

The details

Under the terms of the agreement, Alnylam will provide Tenaya with access to its RNAi technology platform to support the discovery and development of novel cardiovascular disease therapies. Tenaya will be responsible for all research, development, and commercialization activities, while Alnylam is eligible to receive up to $1.1 billion in milestone payments plus royalties on any products that reach the market.

  • The research collaboration was announced on March 5, 2026.

The players

Tenaya Therapeutics

A South San Francisco-based biotech company focused on developing innovative therapies for cardiovascular diseases.

Alnylam Pharmaceuticals

A leading biopharmaceutical company pioneering the translation of RNA interference (RNAi) into a new class of innovative medicines.

Got photos? Submit your photos here. ›

What’s next

The partnership is expected to accelerate Tenaya's cardiovascular drug discovery efforts, with the potential for new treatment candidates to enter clinical development in the coming years.

The takeaway

This collaboration highlights the growing interest in leveraging advanced technologies like RNAi to address unmet needs in cardiovascular medicine, a field with significant potential for innovation and patient impact.